Middle East Respiratory Syndrome: Emergence of a Pathogenic Human Coronavirus.
Middle East Respiratory Syndrome: Emergence of a Pathogenic Human Coronavirus.
复制标题
DOI：
10.1146/annurev-med-051215-031152
复制
发表时间：
2017-01-14
影响因子：
10.5
通讯作者：
Perlman S
中科院分区：
文献类型：
--
作者：
Fehr AR;Channappanavar R;Perlman S
2012年，一种人畜共患冠状病毒被确定为中东呼吸综合征（MERS）的病原体，称为MERS冠状病毒（MERS-CoV）。截至2016年5月12日，该病毒已感染1728名患者，死亡率为36%。虽然MERS-CoV通常引起亚临床或轻度疾病，但感染可导致严重后果，包括合并症患者的急性呼吸窘迫综合征（ARDS）和多器官衰竭。该病毒在阿拉伯半岛和非洲的骆驼中流行，因此构成经常重新引入人群的持续威胁。如果病毒发生变异，增加人与人之间的传染性，疾病流行率将大幅增加。没有治疗剂或疫苗被批准用于MERS;因此，需要开发新的疗法。此外，由于许多MERS病例是在医疗环境中获得的，因此需要采取公共卫生措施并密切关注感染控制措施，以防止更多的MERS爆发。
In 2012, a zoonotic coronavirus was identified as the causative agent of Middle East Respiratory Syndrome (MERS), called MERS Coronavirus (MERS-CoV). Since then, the virus has infected 1728 patients as of 12 May 2016, with a mortality rate of 36%. While MERS-CoV generally causes subclinical or mild disease, infection can result in serious outcomes, including acute respiratory distress syndrome (ARDS) and multi-organ failure in patients with co-morbidities. The virus is endemic in camels in the Arabian peninsula and Africa and thus poses a consistent threat of frequent reintroduction into human populations. Disease prevalence will increase substantially if the virus mutates to increase human-to-human transmissibility. No therapeutics or vaccines are approved for MERS; thus, development of novel therapies is needed. Further, since many MERS cases are acquired in healthcare settings, public health measures and scrupulous attention to infection control practices are required to prevent additional MERS outbreaks.